Medtronic is a compelling investment with its diverse revenue streams, strong growth, and promising product pipeline at an ...

Medtronic (MDT) closed the latest trading day at $89.36, indicating a +0.57% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.61%. Meanwhile, the ...

Ajizian, Medtronic’s chief medical officer of acute care and monitoring, revealed his departure on LinkedIn Thursday. The executive worked in the patient monitoring business before Medtronic ...

Medtronic has been consistently growing at ... From catheters to neurostimulators to continuous glucose monitoring devices, the company has a broad range of products in its portfolio, and it's ...

Medtronic's product portfolio is comprised of a variety of life-saving and life-improving medical devices that include implantable defibrillators, heart valves, insulin pumps, glucose monitoring ...

Medtronic plc hit a sweet spot with its diabetes devices, with the unit leading the company in growth in its first quarter 2025 results. Diabetes device sales grew 11.8% to $647 million for the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Medtronic GI Genius™ system demonstrates AI's capacity to improve diagnostic accuracy by serving as a second set of eyes for clinicians, demonstrating 99.7%-100% sensitivity rate when screening ...

Medtronic found that dropping, bumping, or hits to the MiniMed device could result in a shortened battery life.

Sept 19 (Reuters) - Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's (MDT.N), opens new tab patent rights in nerve ...

Medtronic is bringing on a new chief medical officer for its digital and robotics teams, who it described as one of the top five robotic surgeons in the U.S. James Porter serves as medical ...